BR112015029090A8 - 3,4-dihidroisoquinolin- 2(1h)-ila, seus usos, composição farmacêuticas e sua forma cocristalina - Google Patents

3,4-dihidroisoquinolin- 2(1h)-ila, seus usos, composição farmacêuticas e sua forma cocristalina Download PDF

Info

Publication number
BR112015029090A8
BR112015029090A8 BR112015029090A BR112015029090A BR112015029090A8 BR 112015029090 A8 BR112015029090 A8 BR 112015029090A8 BR 112015029090 A BR112015029090 A BR 112015029090A BR 112015029090 A BR112015029090 A BR 112015029090A BR 112015029090 A8 BR112015029090 A8 BR 112015029090A8
Authority
BR
Brazil
Prior art keywords
dihydroisoquinolin
ila
pharmaceutical composition
compounds
cocrystalline form
Prior art date
Application number
BR112015029090A
Other languages
English (en)
Other versions
BR112015029090A2 (pt
BR112015029090B1 (pt
Inventor
David Beadle Christopher
Daniel Wolfangel Craig
Andrew Coates David
Mehnert Schaus John
Herman Krushinski Joseph Jr
Hao Junliang
Robert Reinhard Matthew
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR112015029090A2 publication Critical patent/BR112015029090A2/pt
Publication of BR112015029090A8 publication Critical patent/BR112015029090A8/pt
Publication of BR112015029090B1 publication Critical patent/BR112015029090B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

resumo patente de invenção: "compostos de 3,4-di-hidroisoquinolin-2(1h)-ila". a presente invenção refere-se a alguns compostos de 3,4-di-hidroisoquinolin-2(1h)-ila, particularmente compostos de fórmula i, e composições farmacêuticas dos mesmos. a invenção adicionalmente proporciona métodos de uso de um composto de fórmula i para tratar transtorno cognitivo associado com doença de parkinson ou esquizofrenia. i
BR112015029090-6A 2013-05-30 2014-05-27 3,4-dihidroisoquinolin-2(1h)-ila, seus usos, composição farmacêuticas e sua forma cocristalina BR112015029090B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361828740P 2013-05-30 2013-05-30
US61/828,740 2013-05-30
US201361905329P 2013-11-18 2013-11-18
US61/905,329 2013-11-18
PCT/US2014/039494 WO2014193781A1 (en) 2013-05-30 2014-05-27 3,4-dihydroisoquinolin-2(1h)-yl compounds

Publications (3)

Publication Number Publication Date
BR112015029090A2 BR112015029090A2 (pt) 2017-07-25
BR112015029090A8 true BR112015029090A8 (pt) 2020-03-17
BR112015029090B1 BR112015029090B1 (pt) 2023-05-09

Family

ID=50983199

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015029090-6A BR112015029090B1 (pt) 2013-05-30 2014-05-27 3,4-dihidroisoquinolin-2(1h)-ila, seus usos, composição farmacêuticas e sua forma cocristalina

Country Status (38)

Country Link
US (1) US8962654B2 (pt)
EP (1) EP3004061B8 (pt)
JP (2) JP6130590B2 (pt)
KR (1) KR101808933B1 (pt)
CN (1) CN105228985B (pt)
AP (1) AP2015008867A0 (pt)
AU (2) AU2014274435B2 (pt)
BR (1) BR112015029090B1 (pt)
CA (1) CA2912849C (pt)
CL (1) CL2015003444A1 (pt)
CR (1) CR20150622A (pt)
CY (1) CY1119361T1 (pt)
DK (1) DK3004061T3 (pt)
DO (1) DOP2015000289A (pt)
EA (1) EA029220B1 (pt)
ES (1) ES2647086T3 (pt)
GT (1) GT201500334A (pt)
HK (1) HK1216314A1 (pt)
HR (1) HRP20171696T1 (pt)
HU (1) HUE034607T2 (pt)
JO (1) JO3316B1 (pt)
LT (1) LT3004061T (pt)
ME (1) ME02838B (pt)
MX (1) MX2015016495A (pt)
MY (1) MY180751A (pt)
NZ (1) NZ713809A (pt)
PE (1) PE20152032A1 (pt)
PH (1) PH12015502658A1 (pt)
PL (1) PL3004061T3 (pt)
PT (1) PT3004061T (pt)
RS (1) RS56294B1 (pt)
SG (1) SG11201509310QA (pt)
SI (1) SI3004061T1 (pt)
TN (1) TN2015000514A1 (pt)
TW (2) TWI691489B (pt)
UA (1) UA118759C2 (pt)
WO (1) WO2014193781A1 (pt)
ZA (1) ZA201508213B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112521367B (zh) 2009-11-27 2024-01-02 基酶有限公司 作为葡糖神经酰胺合酶的抑制剂的无定型和结晶形式的Genz 112638半酒石酸盐
JO3316B1 (ar) * 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
AR106332A1 (es) * 2015-10-23 2018-01-03 Lilly Co Eli Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona
WO2017178377A1 (en) 2016-04-13 2017-10-19 Ucb Biopharma Sprl Tetrahydroisoquinoline derivatives
AU2018225556A1 (en) 2017-02-21 2019-10-03 Emory University Chemokine CXCR4 receptor modulators and uses related thereto
EP3418270A1 (en) 2017-06-19 2018-12-26 Universidad Complutense De Madrid Novel biphenylsulfoximines as allosteric modulators of the dopamine d1 receptor
DK3717025T3 (da) 2017-12-01 2021-11-22 UCB Biopharma SRL Billeddannende midler
TWI725408B (zh) * 2018-04-20 2021-04-21 美商美國禮來大藥廠 多巴胺d1受體正向異位調節劑
EP4417258A2 (en) 2018-12-18 2024-08-21 Eli Lilly and Company Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders
TWI825323B (zh) * 2019-06-18 2023-12-11 美商美國禮來大藥廠 用於製備2-(2,6-二氯苯基)-1-[(1s,3r)-3-(羥甲基)-5-(3-羥基-3-甲基丁基)-1-甲基-3,4-二氫異喹啉-2(1h)-基]乙烯酮之方法及中間物
BR112021022378A2 (pt) * 2019-07-01 2022-03-08 UCB Biopharma SRL Derivado de tetraidroisoquinolina substituído como um modulador alostérico d1 positivo
MX2021015872A (es) 2019-07-01 2022-02-03 UCB Biopharma SRL Un derivado de tetrahidroisoquinolina sustituido como modulador alosterico positivo de d1.
EP4200280B1 (en) * 2020-10-07 2024-02-21 Eli Lilly And Company Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1 receptor positive allosteric modulators
US20240043400A1 (en) 2020-12-03 2024-02-08 UCB Biopharma SRL Octahydroisoquinolinyl Derivatives
KR20230121867A (ko) * 2020-12-18 2023-08-21 유씨비 바이오파마 에스알엘 무정형 고체 분산체
US20240083925A1 (en) * 2020-12-18 2024-03-14 UCB Biopharma SRL Prodrugs of 2-(3,5-Dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone
PE20240632A1 (es) 2020-12-18 2024-03-26 UCB Biopharma SRL Un derivado de tetrahidroisoquinolina sustituido como un modulador alosterico positivo de d1
CN116615198A (zh) * 2020-12-18 2023-08-18 Ucb生物制药有限责任公司 二氢异喹啉基衍生物
WO2022192231A1 (en) 2021-03-08 2022-09-15 Eli Lilly And Company Use of mevidalen and other d1 positive allosteric modulators in the treatment of hallucinations and dementia-related psychosis
EP4304577A1 (en) 2021-03-09 2024-01-17 Eli Lilly And Co. Use of mevidalen and other d1 positive allosteric modulators for slowing of parkinson's disease progression

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68910999T2 (de) 1988-02-19 1994-03-24 Smithkline Beecham Farma 1,2,3,4-Tetrahydroisoquinoline, Verfharen zu ihrer Herstellung und ihre Verwendung als Kappa-Rezeptor Agonisten.
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
US5236934A (en) * 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
US5932590A (en) 1996-12-05 1999-08-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
HUP0101280A3 (en) 1998-02-18 2003-02-28 Neurosearch As Positive ampa receptor modulator compounds and their use
ATE310728T1 (de) 2000-05-11 2005-12-15 Bristol Myers Squibb Co Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga
US7601739B2 (en) 2003-08-08 2009-10-13 Virgina Commonwealth University Compounds having antiestrogenic and tissue selective estrogenic properties, and compounds with anti-androgenic properties for treatment of prostate cancer and androgen receptor dependent diseases
US7541466B2 (en) 2003-12-23 2009-06-02 Genzyme Corporation Tetrahydroisoquinoline derivatives for treating protein trafficking diseases
BRPI0808525A2 (pt) * 2007-03-01 2014-08-19 Janssen Pharmaceutica Nv Compostos de tetraidroisoquinolina como moduladors do receptor de histamina h3
US20120252853A1 (en) * 2011-04-01 2012-10-04 H. Lundbeck A/S Positive allosteric modulators of nicotinic acetylcholine receptor
CN104011021B (zh) 2011-12-21 2016-08-24 埃科特莱茵药品有限公司 杂环衍生物及其作为前列腺素d2受体调节剂的用途
JO3316B1 (ar) * 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل

Also Published As

Publication number Publication date
JP2017178945A (ja) 2017-10-05
JO3316B1 (ar) 2019-03-13
PE20152032A1 (es) 2016-01-28
MX2015016495A (es) 2016-03-01
CR20150622A (es) 2016-01-06
TN2015000514A1 (en) 2017-04-06
HK1216314A1 (zh) 2016-11-04
PH12015502658B1 (en) 2016-03-07
LT3004061T (lt) 2017-11-27
CY1119361T1 (el) 2018-02-14
TWI691488B (zh) 2020-04-21
JP2016520127A (ja) 2016-07-11
TWI691489B (zh) 2020-04-21
TW201940469A (zh) 2019-10-16
ME02838B (me) 2018-01-20
DOP2015000289A (es) 2015-12-31
PL3004061T3 (pl) 2018-01-31
UA118759C2 (uk) 2019-03-11
US20140357664A1 (en) 2014-12-04
AU2014274435B2 (en) 2016-07-14
KR101808933B1 (ko) 2017-12-13
NZ713809A (en) 2019-11-29
US8962654B2 (en) 2015-02-24
PH12015502658A1 (en) 2016-03-07
EA029220B1 (ru) 2018-02-28
HUE034607T2 (en) 2018-02-28
EP3004061A1 (en) 2016-04-13
SG11201509310QA (en) 2015-12-30
AU2016238934A1 (en) 2016-10-27
JP6130590B2 (ja) 2017-05-17
DK3004061T3 (en) 2017-10-23
BR112015029090A2 (pt) 2017-07-25
MY180751A (en) 2020-12-08
WO2014193781A1 (en) 2014-12-04
AU2016238934B2 (en) 2017-08-03
CA2912849C (en) 2017-05-30
SI3004061T1 (sl) 2017-10-30
RS56294B1 (sr) 2017-12-29
JP6387433B2 (ja) 2018-09-05
AP2015008867A0 (en) 2015-11-30
KR20160003110A (ko) 2016-01-08
CL2015003444A1 (es) 2016-07-15
EP3004061B8 (en) 2017-10-04
GT201500334A (es) 2018-11-23
CN105228985A (zh) 2016-01-06
HRP20171696T1 (hr) 2017-12-29
AU2014274435A1 (en) 2015-11-19
CA2912849A1 (en) 2014-12-04
ES2647086T3 (es) 2017-12-19
CN105228985B (zh) 2017-05-10
PT3004061T (pt) 2017-10-19
EA201592082A1 (ru) 2016-04-29
TW201536745A (zh) 2015-10-01
ZA201508213B (en) 2017-08-30
BR112015029090B1 (pt) 2023-05-09
EP3004061B1 (en) 2017-08-30

Similar Documents

Publication Publication Date Title
BR112015029090A8 (pt) 3,4-dihidroisoquinolin- 2(1h)-ila, seus usos, composição farmacêuticas e sua forma cocristalina
BR112014022000A8 (pt) compostos à base de pirazol[1,5-a]pirimidina, seu uso e composições que os compreende
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112017002053A2 (pt) composto de acordo com a fórmula (i), composição farmacêutica, e usos de um composto
EA201591727A1 (ru) Соединения биариламида в качестве ингибиторов киназы
BR112014026703A2 (pt) inibidores de dna-pk
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
BR112015018738A8 (pt) compostos de tetra-hidropirrolotiazina, seus usos, e composição farmacêutica
BR112015011456A2 (pt) compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m
BR112015016315A2 (pt) fluoro-[1,3]oxazinas como inibidores de bace1
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
BR112015000561A2 (pt) inibidores de irak e usos dos mesmos
CO7131375A2 (es) Uracilos sustituidos bicíclicamente y uso de los mismos
BR112014030655A8 (pt) Compostos inibidores de pirimidinil tirosina quinase, e composição farmacêutica que os compreende
BR112014001908A2 (pt) derivados aza heterocíclicos substituídos
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
BR112015026967A8 (pt) fenoxietil di-hidro-1h-isoquinolina, seus usos, e composição farmacêutica
EA201691831A1 (ru) Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов
BR112015028516A2 (pt) tratamento ou prevenção de distúrbios neurodegenerativos com o uso de mentol, linalol e/ou icilina
EA201691788A1 (ru) Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов
EA201690818A1 (ru) Замещенные пиримидиновые соединения и их применение в качестве syk ингибиторов
BR112015010196A2 (pt) métodos de tratar doença do fígado
BR112015006220A2 (pt) agentes antibacterianos de tetrahidroquinolina tricíclica
BR112014011262A8 (pt) compostos substituídos de carboxamida à base de pirazolila substituída e derivados de ureia, seus usos, e composição farmacêutica
BR112014011108A2 (pt) derivados de carboxamida e ureia à base de pirazolila substituída portando uma porção fenila substituída com um grupo contendo so2 como ligantes do receptor de vaniloides

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/05/2014, OBSERVADAS AS CONDICOES LEGAIS